Bioengineered Skin Substitutes Market Top Key Companies, Trends, Segmentations and Forecast by 2030

Technological advancements in wound biologics coupled with innovations in the field of tissue engineering have led to the development of advanced wound healing options and strategies, including bioengineered skin substitutes. These products are being designed to treat a wide range of acute and chronic wounds that pose a serious healthcare threat globally. According to a study published in the International Society for Pharmacoeconomics and Outcomes Research’s Value in Health Journal (January 2018), the economic costs associated with chronic wound management in the U.S. is pegged between $28.1 to $31.7 billion for 8.2 million affected patients. Hence, increasing incidence of chronic wounds, as well as rising cases of burns injuries, are actively promoting the growth of the global bioengineered skin substitutes market. Further, the factors contributing to the huge demand for skin substitutes are their emerging applications, superior property, and huge investment by government and federal agencies.

The bioengineered skin substitutes market was estimated at $1,305.8 Million in 2019 and is expected to reach $4,330.2 Million by the end of 2030 with CAGR of 11.90%during the forecast period .

The bioengineered skin substitutes market is currently at a blooming phase, with the presence of various juggernauts such as AbbVie, Inc., Integra LifeSciences Corporation, Smith & Nephew plc, and Stryker Corporation, and other medium and small-medium enterprises that are offering a wide range of bioengineered skin substitutes products in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.

Market Segmentation

• By Product: Allogenic, Autologous, Xenogeneic, Acellular, and Others

• By Application: Chronic Wounds and Acute Wounds

• By End User: Hospitals, Specialty Clinics, Wound Care Centers, and Others

Regional Segmentation

• North America – U.S., Canada

• Europe – Germany, U.K., France, Italy, Spain, and Rest-of-Europe

• Asia-Pacific – China, Australia, Japan, India, South Korea, and Rest-of-Asia-Pacific

• Rest-of-the-World

Growth Drivers

• Increasing Prevalence of Diabetes and Diabetic Foot Ulcers

• Rising Cases of Chronic Wounds and Burn Injuries

• Increasing Funds/Aids by the Government for Research Purposes

• Growing Prominence of Regenerative Medicine and Tissue Engineering Products

• Increasing Obesity

Market Challenges

• Biocompatibility Issues and Stringent Regulations

• Limitations of Skin Substitutes

• Expensive Treatment

Market Opportunities

• Patient Awareness and Improved Lifestyle in Emerging Economics

• Advancing Inclination Toward Acellular Skin Substitutes

Key Companies Profiled

Anika Therapeutics, Inc., AbbVie, Inc., Smith & Nephew plc, Integra LifeSciences Corporation, Boston Scientific Corporation, Organogenesis, Inc., Mölnlycke Health Care AB, Vericel Corporation, Stryker Corporation, Zimmer Biomet, and Aroa Biosurgery, Cook Biotech Incorporated, Promethean LifeSciences, Inc., XCELLentis NV, and AlloSource.

Request a Sample - https://bisresearch.com/requestsample?id=1024&type=download

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development. Impact Several techniques are employed in ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Market Research Reports

Search This Blog